Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 4
1(25.0%)
4Total
N/A(3)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT07565662Not ApplicableCompleted

Intrathecal Dexmedetomidine and Acute Neuropathic Pain After Lower Limb Amputation

Role: lead

NCT05503303Completed

T1D, Metabolic Syndrome and Insulin Resistance

Role: lead

NCT05235672Completed

Detection of LADA in a Hospital in the Mexican Southeast

Role: lead

NCT04363541Not ApplicableRecruiting

Local Thermotherapy for Patients With Mild-to-moderate COVID-19

Role: collaborator

NCT03978286Phase 4Completed

Vortioxetine vs Sertraline in Mexicans

Role: lead

NCT02606812Not ApplicableUnknown

Effect of Food Consumption on microRNA Related to Metabolic Syndrome

Role: lead

All 6 trials loaded